Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a... Breast Cancer Res Treat (2017) 165:329–341 DOI 10.1007/s10549-017-4304-7 CLINICAL TRIAL Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial 1 2 3 4 • • • • Javier Corte ´s Hope S. Rugo Ahmad Awada Chris Twelves 5 6 7 8 • • • • Edith A. Perez Seock–Ah Im Patricia Go ´ mez-Pardo Lee S. Schwartzberg 9 10 11 12 ´ • • • • Veronique Dieras Denise A. Yardley David A. Potter Audrey Mailliez 1 13 14 14 • • • • Alvaro Moreno-Aspitia Jin-Seok Ahn Carol Zhao Ute Hoch 14 15 16 • • Mary Tagliaferri Alison L. Hannah Joyce O’Shaughnessy Received: 12 May 2017 / Accepted: 16 May 2017 / Published online: 13 June 2017 The Author(s) 2017. This article is an open access publication Abstract those with treated, stable brain metastases. The primary Purpose Conventional chemotherapy has limited activity endpoint, overall survival (OS), was assessed in a pre-de- in patients with breast cancer and brain metastases fined subgroup of BCBM patients; an exploratory post hoc (BCBM). Etirinotecan pegol (EP), a novel long-acting analysis adjusting for the diagnosis-specific http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Breast Cancer Research and Treatment Springer Journals

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

Loading next page...
 
/lp/springer_journal/prolonged-survival-in-patients-with-breast-cancer-and-a-history-of-Q0OzSlt0Uu
Publisher
Springer US
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Oncology
ISSN
0167-6806
eISSN
1573-7217
D.O.I.
10.1007/s10549-017-4304-7
Publisher site
See Article on Publisher Site

Abstract

Breast Cancer Res Treat (2017) 165:329–341 DOI 10.1007/s10549-017-4304-7 CLINICAL TRIAL Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial 1 2 3 4 • • • • Javier Corte ´s Hope S. Rugo Ahmad Awada Chris Twelves 5 6 7 8 • • • • Edith A. Perez Seock–Ah Im Patricia Go ´ mez-Pardo Lee S. Schwartzberg 9 10 11 12 ´ • • • • Veronique Dieras Denise A. Yardley David A. Potter Audrey Mailliez 1 13 14 14 • • • • Alvaro Moreno-Aspitia Jin-Seok Ahn Carol Zhao Ute Hoch 14 15 16 • • Mary Tagliaferri Alison L. Hannah Joyce O’Shaughnessy Received: 12 May 2017 / Accepted: 16 May 2017 / Published online: 13 June 2017 The Author(s) 2017. This article is an open access publication Abstract those with treated, stable brain metastases. The primary Purpose Conventional chemotherapy has limited activity endpoint, overall survival (OS), was assessed in a pre-de- in patients with breast cancer and brain metastases fined subgroup of BCBM patients; an exploratory post hoc (BCBM). Etirinotecan pegol (EP), a novel long-acting analysis adjusting for the diagnosis-specific

Journal

Breast Cancer Research and TreatmentSpringer Journals

Published: Jun 13, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off